These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34785872)

  • 1. Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2.
    Sengupta S; Handoo A; Pande R; Kapoor RK
    Indian J Clin Biochem; 2022 Oct; 37(4):480-486. PubMed ID: 34785872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
    Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
    BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Success rate of Remdesivir, Convalescent Plasma, and Tocilizumab in moderate to severe Covid-19 pneumonia: our experience in a tertiary care center.
    Mohanty B; Sunder A; Satyanarayan B; Kumar M; Shukla R; Ahmed A
    J Family Med Prim Care; 2021 Nov; 10(11):4236-4241. PubMed ID: 35136795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in plasma D-dimer level in severe SARS-CoV-2 infection can be an indicator of fibrinolysis suppression: Case reports.
    Manzoor D; Bui C; Makhoul E; Luthringer D; Marchevsky A; Volod O
    Medicine (Baltimore); 2021 Apr; 100(15):e25255. PubMed ID: 33847623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab and Thromboembolism in COVID-19: A Retrospective Hospital-Based Cohort Analysis.
    Chan KH; Patel B; Podel B; Szablea ME; Shaaban HS; Guron G; Slim J
    Cureus; 2021 May; 13(5):e15208. PubMed ID: 34178527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship.
    D'Ardes D; Boccatonda A; Cocco G; Fabiani S; Rossi I; Bucci M; Guagnano MT; Schiavone C; Cipollone F
    World J Gastroenterol; 2022 Mar; 28(11):1102-1112. PubMed ID: 35431501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between COVID-19 Outcomes and Patient Characteristics: A Study in an Inner-City Community Hospital.
    Almonte M; Au XY; Ali M; Rajabalee N; Hasan S; Shibre T; Li Y; Kaplan AC
    Cureus; 2021 Aug; 13(8):e17255. PubMed ID: 34540480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.
    Farooqi F; Dhawan N; Morgan R; Dinh J; Nedd K; Yatzkan G
    Trop Med Infect Dis; 2020 Jul; 5(3):. PubMed ID: 32635353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients.
    Li C; Jiang J; Wang F; Zhou N; Veronese G; Moslehi JJ; Ammirati E; Wang DW
    J Mol Cell Cardiol; 2020 Oct; 147():74-87. PubMed ID: 32827510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Mortality Amongst Tocilizumab Administered COVID-19 Asian Indians: A Predictive Study From a Tertiary Care Centre.
    Desai HD; Sharma K; Parikh A; Patel K; Trivedi J; Desai R; Patel PP; Patel Z; Patel S; Kini S
    Cureus; 2021 Feb; 13(2):e13116. PubMed ID: 33717715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia.
    Jordan SC; Zakowski P; Tran HP; Smith EA; Gaultier C; Marks G; Zabner R; Lowenstein H; Oft J; Bluen B; Le C; Shane R; Ammerman N; Vo A; Chen P; Kumar S; Toyoda M; Ge S; Huang E
    Clin Infect Dis; 2020 Dec; 71(12):3168-3173. PubMed ID: 32575124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
    Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
    Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Study of Cytokine Storm Treatment in Patients with COVID-19 Pneumonia Using Immunomodulators.
    Marc F; Moldovan CM; Hoza A; Magheru S; Ciavoi G; Farcas DM; Sachelarie L; Calin G; Romila L; Damir D; Naum AG
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35629072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.